AbbVie Inc. (ABBV)

79.46
NYSE : Health Technology
Prev Close 79.50
Day Low/High 78.02 / 80.08
52 Wk Low/High 75.62 / 107.25
Avg Volume 5.71M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 117.53B
EPS 3.70
P/E Ratio 22.21
Div & Yield 4.28 (5.15%)

Latest News

MC10, Inc. And AbbVie (NYSE:ABBV) Announce Clinical Trials In Multiple Sclerosis Using The BioStamp NPoint® System

MC10, Inc. And AbbVie (NYSE:ABBV) Announce Clinical Trials In Multiple Sclerosis Using The BioStamp NPoint® System

MC10, Inc., a healthcare technology company specializing in wearable digital health sensors, and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the companies are working together on clinical trials designed to...

AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation With Boehringer Ingelheim

AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation With Boehringer Ingelheim

NORTH CHICAGO, Ill., May 14, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that it has resolved U.

AbbVie To Present At The UBS Global Healthcare Conference

AbbVie To Present At The UBS Global Healthcare Conference

NORTH CHICAGO, Ill., May 14, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the UBS Global Healthcare Conference on Tuesday, May 21, 2019.

AbbVie To Present At The Bank Of America Merrill Lynch Healthcare Conference

AbbVie To Present At The Bank Of America Merrill Lynch Healthcare Conference

NORTH CHICAGO, Ill., May 7, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019.

European Commission Approves SKYRIZI™ (risankizumab) For The Treatment Of Moderate To Severe Plaque Psoriasis

European Commission Approves SKYRIZI™ (risankizumab) For The Treatment Of Moderate To Severe Plaque Psoriasis

- Approval based on results from clinical studies showing high rates of skin clearance at 16 weeks; this clearance was durable at one year with every 12-week dosing[1-4]

AbbVie To Present New And Updated Data Of Investigational Medicines For Parkinson's Disease And Multiple Sclerosis At 2019 American Academy Of Neurology Annual Meeting

AbbVie To Present New And Updated Data Of Investigational Medicines For Parkinson's Disease And Multiple Sclerosis At 2019 American Academy Of Neurology Annual Meeting

- Presentations include updates on ABBV-951, a subcutaneous infusion therapy for Parkinson's disease (PD), and elezanumab, a monoclonal antibody directed against repulsive guidance molecule A (RGMa) in multiple sclerosis (MS), among other data to be presented

AbbVie Climbs Earnings Beat, Guidance Boost

AbbVie Climbs Earnings Beat, Guidance Boost

AbbVie climbs after beating first-quarter estimates and raising full-year guidance.

Earnings, Earnings and More Earnings, Facebook Results: Market Recon

Earnings, Earnings and More Earnings, Facebook Results: Market Recon

As we have seen so far, in terms of market reaction, there is great reward at the point of sale in beating expectations.

AbbVie Reports First-Quarter 2019 Financial Results

AbbVie Reports First-Quarter 2019 Financial Results

- Reports First-Quarter Diluted EPS of $1.65 on a GAAP Basis; Adjusted Diluted EPS of $2.14 Reflects Growth of 14.4 Percent

Microsoft, Facebook, Tesla, Amazon and Deutsche Bank - 5 Things You Must Know

Microsoft, Facebook, Tesla, Amazon and Deutsche Bank - 5 Things You Must Know

U.S. stock futures trade mixed on Thursday; Amazon, Intel and Comcast report earnings; Microsoft jumps as third-quarter earnings beat analysts' expectations; Facebook sets aside $3 billion for expected fine from Federal Trade Commission.

AbbVie Expands Immunology Portfolio In The U.S. With FDA Approval Of SKYRIZI™ (risankizumab-rzaa) For Moderate To Severe Plaque Psoriasis

AbbVie Expands Immunology Portfolio In The U.S. With FDA Approval Of SKYRIZI™ (risankizumab-rzaa) For Moderate To Severe Plaque Psoriasis

- Approval based on clinical trials showing people treated with SKYRIZI™ (risankizumab-rzaa) every 12 weeks - four doses a year after two initial doses - achieved high levels of durable skin clearance at 16 weeks and maintained this response at one year[1-3]

Health Canada Approves SKYRIZI™ (risankizumab) For The Treatment Of Moderate To Severe Plaque Psoriasis

Health Canada Approves SKYRIZI™ (risankizumab) For The Treatment Of Moderate To Severe Plaque Psoriasis

SKYRIZI™(risankizumab)  is  a novel, humanized immunoglobulin monoclonal antibody designed to selectively inhibit IL-23 by binding to its p19 subunit to treat moderate to severe plaque psoriasis 1 .

Are These Stocks the Best of the Best?

Are These Stocks the Best of the Best?

Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.

Bullish Start to Earnings: Cramer's 'Mad Money' Recap (Friday 4/12/19)

Bullish Start to Earnings: Cramer's 'Mad Money' Recap (Friday 4/12/19)

Jim Cramer says this positive start will be hard to sustain this earnings season. He's got your game plan for next week.

Square, Cabot Oil & Gas, AbbVie: 'Mad Money' Lightning Round

Square, Cabot Oil & Gas, AbbVie: 'Mad Money' Lightning Round

Jim Cramer weighs in on Square, Cabot Oil & Gas, AbbVie, Philip Morris International, Bunge, Greenbrier Companies, LCI Industries and more.

AbbVie To Host First-Quarter 2019 Earnings Conference Call

AbbVie To Host First-Quarter 2019 Earnings Conference Call

NORTH CHICAGO, Ill., April 3, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its first-quarter 2019 financial results on Thursday, April 25 before the market opens.

AbbVie Provides Update On VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program

AbbVie Provides Update On VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program

NORTH CHICAGO, Ill., March 19, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.

AbbVie Announces Multiple Milestones For Phase 3 CLL14 Venetoclax Study Of Fixed Duration Treatment In Previously-Untreated Chronic Lymphocytic Leukemia Patients

AbbVie Announces Multiple Milestones For Phase 3 CLL14 Venetoclax Study Of Fixed Duration Treatment In Previously-Untreated Chronic Lymphocytic Leukemia Patients

- The Phase 3 CLL14 trial of venetoclax in combination with obinutuzumab is the first randomized clinical trial to examine a chemotherapy-free treatment given for a fixed duration in previously-untreated patients with chronic lymphocytic leukemia (CLL) and comorbidities

What Is a Dividend Aristocrat and How Do You Join the Club?

What Is a Dividend Aristocrat and How Do You Join the Club?

It's no secret why the list of S&P 500 'dividend aristocrats' is a who's-who of great Wall Street brands. Here's what makes them so special.

AbbVie To Present At The Barclays Global Healthcare Conference

AbbVie To Present At The Barclays Global Healthcare Conference

NORTH CHICAGO, Ill., March 1, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Barclays Global Healthcare Conference on Wednesday, March 13, 2019.

AbbVie Receives CHMP Positive Opinion For Risankizumab (SKYRIZI™) For The Treatment Of Moderate To Severe Plaque Psoriasis

AbbVie Receives CHMP Positive Opinion For Risankizumab (SKYRIZI™) For The Treatment Of Moderate To Severe Plaque Psoriasis

- CHMP positive opinion, supported by data from the pivotal Phase 3 program evaluating more than 2,000 patients with moderate to severe plaque psoriasis, will now be reviewed by the European Commission(1-3)

5 Attractive Ways to Invest in Oncology

5 Attractive Ways to Invest in Oncology

Experts offer their top stock ideas in oncology detection and treatment.

AbbVie Becomes #179 Most Shorted S&P 500 Component, Replacing CBRE Group

AbbVie Becomes #179 Most Shorted S&P 500 Component, Replacing CBRE Group

The most recent short interest data has been released for the 02/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

AbbVie To Present At The Cowen Health Care Conference

AbbVie To Present At The Cowen Health Care Conference

NORTH CHICAGO, Ill., Feb.

What's Keeping You Up?: Cramer's 'Mad Money' Recap (Wednesday 2/27/19)

What's Keeping You Up?: Cramer's 'Mad Money' Recap (Wednesday 2/27/19)

Jim Cramer says if you focus on what's going right, you'll sleep better and do a lot better with your money, too.

Waste Management, Weight Watchers, Centene: 'Mad Money' Lightning Round

Waste Management, Weight Watchers, Centene: 'Mad Money' Lightning Round

Jim Cramer weighs in on Waste Management, Weight Watchers, Centene, Aurinia Pharmaceuticals, Activision Blizzard, AbbVie, Cronos Group and more.

TheStreet Quant Rating: B- (Buy)